Serial crystallography has enabled the study of complex biological questions through the determination of biomolecular structures at room temperature using low X-ray doses. Furthermore, it has enabled the study of protein dynamics by the capture of atomically resolved and time-resolved molecular movies. However, the study of many biologically relevant targets is still severely hindered by high sample consumption and lengthy data-collection times. By combining serial synchrotron crystallography (SSX) with 3D printing, a new experimental platform has been created that tackles these challenges. An affordable 3D-printed, X-ray-compatible microfluidic device (3D-MiXD) is reported that allows data to be collected from protein microcrystals in a 3D flow with very high hit and indexing rates, while keeping the sample consumption low. The miniaturized 3D-MiXD can be rapidly installed into virtually any synchrotron beamline with only minimal adjustments. This efficient collection scheme in combination with its mixing geometry paves the way for recording molecular movies at synchrotrons by mixing-triggered millisecond time-resolved SSX.

Electron microscopy of macromolecular structures is an approach that is in increasing demand in the field of structural biology. The automation of image acquisition has greatly increased the potential throughput of electron microscopy. Here, the focus is on the possibilities in Scipion to implement flexible and robust image-processing workflows that allow the electron-microscope operator and the user to monitor the quality of image acquisition, assessing very simple acquisition measures or obtaining a first estimate of the initial volume, or the data resolution and heterogeneity, without any need for programming skills. These workflows can implement intelligent automatic decisions and they can warn the user of possible acquisition failures. These concepts are illustrated by analysis of the well known 2.2 Å resolution β-galactosidase data set.

As economic expansion and development fragments the forest landscape of central India, the species that rely on that habitat—including endangered tigers and leopards—face dwindling populations […]

The post Forest corridors essential to gene flow in India’s leopard and tiger populations appeared first on Smithsonian Insider.

Roses, carnations and lilies are today among the most popular flowers people use to express sympathy and condolence. The simple act of sending flowers to […]

The post Funeral flowers in the Stone Age: Q&A with Smithsonian anthropologist Reuven Yeshurun appeared first on Smithsonian Insider.

Structural investigations of amorphous and nanocrystalline phases forming in solution are historically challenging. Few methods are capable of in situ atomic structural analysis and rigorous control of the system. A mixed-flow reactor (MFR) is used for total X-ray scattering experiments to examine the short- and long-range structure of phases in situ with pair distribution function (PDF) analysis. The adaptable experimental setup enables data collection for a range of different system chemistries, initial supersaturations and residence times. The age of the sample during analysis is controlled by adjusting the flow rate. Faster rates allow for younger samples to be examined, but if flow is too fast not enough data are acquired to average out excess signal noise. Slower flow rates form older samples, but at very slow speeds particles settle and block flow, clogging the system. Proper background collection and subtraction is critical for data optimization. Overall, this MFR method is an ideal scheme for analyzing the in situ structures of phases that form during crystal growth in solution. As a proof of concept, high-resolution total X-ray scattering data of amorphous and crystalline calcium phosphates and amorphous calcium carbonate were collected for PDF analysis.

The post Conrad Labandiera, Smithsonian palentologist, studies fossils to learn how insects got along before flowering plants arrived appeared first on Smithsonian Insider.

Flowers are usually associated with butterflies, but not the Dutchman’s Pipe (Aristolochia grandiflora). This deciduous vine, native to Brazil, has large flowers that emit an odor of decaying flesh, which attracts flies and beetles.

The post Video: Smithsonian horticulturalist Janet Draper discusses the pollination of the pelican flower appeared first on Smithsonian Insider.

Recent botanical exploration efforts in the rugged Marquesas Islands (French Polynesia) have increased the known flora of the archipelago by an impressive 20 percent. Field research and collecting in conjunction with the Vascular Flora of the Marquesas Islands and Flore de la Polynesie française projects have yielded 62 new species of ferns and flowering plants bringing the total native species to 360, of which 18 are newly described and illustrated in a special issue of PhytoKeys.

The post Marquesas Islands in French Polynesia yield 18 new species of rare ferns and flowering plants appeared first on Smithsonian Insider.

Fulcaldea stuessyi is a newly discovered member of the Barnadesioideae, a subfamily of the Compositae, or sunflower family of flowering plants. It was found in northeastern […]

The post Fulcaldea stuessyi is newly discovered member of the Barnadesioideae, a subfamily of the Compositae, or sunflower family of flowering plants, appeared first on Smithsonian Insider.

What plant species has just been discovered but is almost gone? Bidens meyeri–a just discovered flowering plant from the small South Pacific island of Rapa, […]

The post New South Pacific cliff flower is critically endangered appeared first on Smithsonian Insider.

Rattlesnake, zebra and peacock plants have a new wild relative, discovered by Rodolfo Flores, Panamanian botanist and intern at the Smithsonian Tropical Research Institute (STRI). […]

The post Smithsonian Botanist Discovers New Ground-Flowering Plant in Panama appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Flowbird Group has announced recent developments that limit...

Patt Morrison's ensemble for Aug 8, 2013.; Credit: Dave Coelho/KPCC

What shall we call this color scheme? How about ‘Manhattan Mermaid’?

The petrel blues, the turquoises, the aquas – and then that uptown/downtown black, in this case a black linen duster over a Peter Max-style splashy-print silk dress. The way the hem pools at the sides a bit reminds me of the cut of Pre-Raphaelite ladies’ tunics; I’d love to dress “period” for a week to see whether I’d like it.

Imagine, a week of hoop skirts … a week of 1950s tailleurs … a week of bustles … a week of hobble skirts … a week of liberated Pre-Raphaelite velvet gowns!

The hat is so unmistakably summer in fabric and color that it doesn’t get out of the hatbox as much as it should, poor thing. And the shoes – I did not get them together, honest, but even though the prints don’t match, it’s the dissonance that makes them work better together than if they had.

The fabric is a very textured canvas and printed like batik. [They are not the soul of comfort – oh what a dreadful pun, but is there any other kind of pun? – but they look smart hooked over the railing of a chair in a chic bistro, which is where I intend to take them!]

And the bracelets, one from a great-aunt who had a fine eye for jewelry – the turquoise is almost Persian, it’s so green, but it’s more likely to be American. The cuff is definitely Southwest, with the rope-pattern trim and the irregularly shaped bezels, although the turquoises themselves are symmetrical.

Because I’m left-handed, my right arm bears the singular honor of being “ornamental,” and bearing the burden of the bling.

Summer on, ladies!

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Groundwater is the earth’s largest freshwater resource and is vital for irrigation and global food production. In dry periods farmers pump groundwater to water crops, this is already happening at an unsustainable level in many places — exceeding the rate at which rain and rivers can refill the groundwater stores. This study seeks to identify where groundwater pumping is affecting stream flows and estimates where and when environmentally critical stream flows — required to maintain healthy ecosystems — can no longer be sustained.

New research from Sweden identifies the characteristics of substance flow analyses that make them useful to policy makers. Substance flow analyses that focus on measuring rather than modelling pollution and which are aligned to existing measures are more likely to influence policy.

Researchers have developed a new energy map that traces the flow of global energy from the fuel sources to the final services provided. The study provides new insight into the potential of energy efficiency measures by focusing on technologies rather than economic sectors.

A new tool to help planners choose urban designs that positively influence flows of energy, carbon, water and pollutants in cities is presented in a recent study. It is designed to integrate scientific knowledge into the planning process and support cities in achieving sustainability objectives.

A new tool to increase the efficiency of water supply and distribution networks is presented by a new study. By using a framework which encompasses both water sources and demands, researchers have developed an integrated system that has showed promising results when applied to the complex urban water system of Athens.

Human water consumption has increased the frequency and intensity of periods of abnormally low flow in streams, new research suggests. The frequency of these events increased by 30% globally, largely due to use of water for irrigation, the researchers conclude.

Human activities have caused phosphorus to accumulate in soils and water bodies, creating a legacy that could last for decades, new research shows. A study of three major river basins highlights better sewage treatment facilities and reduced fertiliser use as key reasons for an overall decline in phosphorus levels in the Thames River basin, UK, since the late 1990s.

Google has announced machine images, a new type of Compute Engine resource that contains all the information people need to create, backup or restore a virtual machine, reducing the amount of time people spend managing their Cloud environment.

Pollination of intensively farmed, flowering crops could affect the pollination of wild plants in neighbouring fields, according to a study by German researchers. In their one-year study, they found fewer bees visited wild plants that are close to oilseed rape fields, although the longer-term picture is less clear. The researchers warn that increasing cultivation of biofuel crops could possibly reduce wild flower populations.

Falling levels of insect pollination are causing declining yields of important agricultural crops. However, new research from South Africa now indicates that planting small patches of native flowers in agricultural fields can be a profitable and sustainable method of increasing pollination and yield.

Planting early-flowering crops, such as oilseed rape, boosts the numbers of bumblebees available to pollinate late-flowering crops, such as sunflowers, according to recent research. Carefully managing the timing and coverage of flowering crops in the landscape could therefore ensure pollination services and increase yields, say the researchers.

The pollination benefits of planting field margins with wildflowers can outweigh the costs of set-up and maintenance, a new study suggests. On US blueberry farms wildflower strips resulted in double the number of wild bees on adjacent crops and significantly increased yield, the researchers found.

Among the ecological effects of climate change are changes to the timing of natural events, such as flowering. To understand why these phenological changes affect reproduction, this study manipulated conditions in a spring herb to prompt premature flowering. This exposed the flowers to frost, and resulting damage caused dramatic reductions in plant reproduction, suggesting that climate change may threaten plant survival.

Agri-environment schemes (AES) have been implemented throughout Europe to mitigate against the negative effects of agricultural intensification. Although these schemes have shown positive effects on the abundance and richness of certain species and taxa, the impact of AES on reproduction of target species at the local and landscape scale is poorly understood. This large-scale study looked for the effect of selected AE measures on bumblebee reproduction. Results indicate that bumblebee reproduction is significantly higher on sown flower patches when compared to conventional management. Although the increase is most pronounced at the plot scale, higher reproduction was found in landscapes surrounding larger sown plots (at least one hectare) compared to smaller sown plots.

A study of wildflower planting within agri-environment schemes has demonstrated that the practice can support a diverse array of economically beneficial insect species, not just prominent pollinators such as wild bees and hoverflies. The study demonstrates the high conservation potential of wildflower planting within agricultural landscapes and the value of insects outside the traditional focus of conservation efforts.

This study assessed the implementation of the ‘Flowering Meadows’ agri-environment scheme in France, a results-based scheme which encourages farmers to conserve meadows in the Bauges, Haut Jura and Vercors natural parks. While there was limited change in agricultural practices, the scheme did help to maintain meadow habitats. Farmers also welcomed the results-based payments approach, which gave them greater responsibility for and flexibility in managing their farms.

Free-flowing rivers (FFRs) support a complex, dynamic and diverse range of global ecosystems, and provide important economic and societal services. However, infrastructure built to use these services — most notably 2.8 million dams worldwide — has caused many rivers to become fragmented and disconnected, affecting river biodiversity and ecosystem services. This study constructed a global information system with which to map the fine-scale dynamics and fragmentation of FFRs and to determine how human pressures affect the world’s river systems.

Someone recently challenged me to convert the curling simulator we published a few years ago (See this post and this post) to take advantage of new features not available at that time: App Designer and Stateflow for MATLAB.... read more >>

Grey has an iMac Pro, Myke has thoughts about vlogging, and they both have Yearly Theme updates.

Those taking their government-approved daily walk have been warned not to pick wildflowers - or risk facing an eye-watering £5,000 fine.

From rare orchids to a flower that lives for just a few hours, these blooms are the pick of the crop.

BP is coming under criticism for buying 'gulf oil spill' search advertising on Google. Will the company's attempt to redirect online traffic backfire?

A new report from Climate Central finds that most of the overflow was caused by coastal flooding, which was made worse by rising sea levels.

The stench of foul-smelling flowers attracts insects that aid in their pollination.

In addition to surreal garden installations, the Hampton Court Flower Show hosts talks and demonstrations focusing on environmental issues.

The vernal equinox marks a shift in seasons, and nothing says that better than flowers bursting into bloom.

Massive trees, towering over 250 feet, only flower once every 7 to 10 years.

New research finds that people who don't like music might have lower blood flow in certain parts of their brains.

Researchers trace back the origin of all flowering plants to a single ancestor using a sophisticated data crunch.

Chris Burley and Ei Ei Khin have an ambitious goal: Grow 1 million wildflowers to help threatened honeybee populations.

The apiarian artery is the buzziest infrastructure project in Scandinavia.

Neolithic humans in the Wadi Faynan region of southern Jordan may have polluted the river while first learning how to smelt.